332 related articles for article (PubMed ID: 8519050)
21. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
[No Abstract] [Full Text] [Related]
22. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
23. Biotech patents-business as usual?
Lawrence S
Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
[No Abstract] [Full Text] [Related]
24. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
Ainsworth MA
Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
[TBL] [Abstract][Full Text] [Related]
25. Biotechnology patenting policy in the European Union--as exemplified by the development in Germany.
Schrell A; Bauser H; Brunner H
Adv Biochem Eng Biotechnol; 2007; 107():13-39. PubMed ID: 17522818
[TBL] [Abstract][Full Text] [Related]
26. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
27. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
Smart A; Martin P
Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
[TBL] [Abstract][Full Text] [Related]
28. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
29. Future European health care: cost containment, health care reform and scientific progress in drug research.
Emilien G
Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
[TBL] [Abstract][Full Text] [Related]
30. Path to approval proves rocky for copycat biodrugs.
Wadman M
Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
[No Abstract] [Full Text] [Related]
31. [Drug evaluation: new requirements and perspectives].
Addis A; Rocchi F
Recenti Prog Med; 2006 Nov; 97(11):618-25. PubMed ID: 17252718
[TBL] [Abstract][Full Text] [Related]
32. The US drug safety system: role of the pharmaceutical industry.
Gibson BR; Suh R; Tilson H
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
[TBL] [Abstract][Full Text] [Related]
33. The patentability of antibodies in the United States.
Lu DL; Collison AM; Kowalski TJ
Nat Biotechnol; 2005 Sep; 23(9):1079-80. PubMed ID: 16151395
[TBL] [Abstract][Full Text] [Related]
34. Enabling Europe to innovate.
Dearing A
Science; 2007 Jan; 315(5810):344-7. PubMed ID: 17234939
[TBL] [Abstract][Full Text] [Related]
35. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
Celis P; Silvester G
Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
[TBL] [Abstract][Full Text] [Related]
36. New safe medicines faster: A proposal for a key action within the European union's 6th framework programme.
Bjerrum OJ
Pharmacol Toxicol; 2000; 86 Suppl 1():23-6. PubMed ID: 10905750
[TBL] [Abstract][Full Text] [Related]
37. Moving goalposts--regulatory oversight of antibacterial drugs.
Brenner R; Ellis-Grosse EJ; Echols R
Nat Biotechnol; 2006 Dec; 24(12):1515-20. PubMed ID: 17160053
[TBL] [Abstract][Full Text] [Related]
38. Industry perspectives on ICH guidelines.
Rockhold FW
Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
[TBL] [Abstract][Full Text] [Related]
39. An industry imperiled by regulatory bottlenecks.
Naughton G
Nat Biotechnol; 2001 Aug; 19(8):709-10. PubMed ID: 11479550
[No Abstract] [Full Text] [Related]
40. Approval times for supplemental indications for recombinant proteins.
Gosse ME; Nelson TF
Nat Biotechnol; 1997 Feb; 15(2):130-4. PubMed ID: 9035135
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
